Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
Date:2/17/2009

ing statements. These statements are often, but not always, made through the use of words or phrases such as believe, will, expect, anticipate, estimate, intend, plan and would. For example, statements concerning Gen-Probe's financial condition, possible or expected results of operations, financial guidance, regulatory approvals, future milestone payments, growth opportunities, proposed acquisition of Tepnel Life Sciences, PLC, and plans and objectives of management are all forward-looking statements. Forward-looking statements are not guarantees of performance. They involve known and unknown risks, uncertainties and assumptions that may cause actual results, levels of activity, performance or achievements to differ materially from those expressed or implied. Some of these risks, uncertainties and assumptions include but are not limited to: (i) the risk that we may not achieve our expected 2009 growth, revenue, earnings or other financial targets, (ii) the possibility that the market for the sale of our new products, such as our TIGRIS system, APTIMA Combo 2 assay, PROCLEIX ULTRIO assay and PROGENSA PCA3 assay, may not develop as expected, (iii) the enhancement of existing products and the development of new products, including products, if any, to be developed under our recent industrial collaborations, may not proceed as planned, (iv) the risk that new products or indications may not be approved by regulatory authorities or become commercially available in the time frame we anticipate, or at all, (v) the risk that we may not be able to compete effectively, (vi) the risk that we may not be able to maintain our current corporate collaborations and enter into new corporate collaborations or customer contracts, (vii) the risk that our proposed acquisition of Tepnel may not be completed on the expected timeline, or at all, (viii) our dependence on Novartis, Siemens (as assignee of Bayer) and other third parties for the distribution of some of our products, (ix) ou
'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
2. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
3. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
4. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
5. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
8. Gen-Probe to Webcast Two Upcoming Investor Presentations
9. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
10. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
11. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... 01, 2014 The European gas chromatography systems ... analysis and forecast of revenue. The gas chromatography systems market ... is estimated to grow to around $247.6 million by 2018, ... Browse through the TOC of the European gas chromatography systems ... This also provides a glimpse of the segmentation of gas ...
(Date:8/1/2014)... According to a new market research report of ... Types, Applications (Automotive, Petrochemical, Consumer Utility, Glass, and Aerospace ... - Analysis & Forecast to 2010 - 2020", published ... to $1.42 Billion by 2020 at a CAGR of ... grow to $238.17 Million by 2020 at a CAGR ...
(Date:8/1/2014)... Society of America (GSA) the nation,s ... aging has chosen J. Jill Suitor, PhD, ... the Distinguished Career Contribution to Gerontology Award. , ... individual whose theoretical contributions have helped bring about ... original and elegant research designs addressing a significant ...
(Date:8/1/2014)... of America (GSA) the nation,s largest ... has chosen Madonna Harrington Meyer, PhD, of ... University of Luxembourg; and Philipp Hessel, MA, MSc, ... of Economics and Political Science as the 2014 ... , These distinguished honors recognize insightful and innovative ...
(Date:8/1/2014)... August 01, 2014 Lifeinsurancenomedicalexam.info has ... life insurance for clients who have high cholesterol levels. ... still find and qualify for no medical exam life ... requiring any background medical check-ups. , Since there are ... cholesterol level will qualify in just a few minutes. ...
Breaking Medicine News(10 mins):Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 2Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 3Health News:European Gas Chromatography (GC) Systems Market is Expected to Reach $247.6 Million in 2018 - New Report by MicroMarket Monitor 4Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 2Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 3Health News:Thermocouples Market worth $1.42 Billion & High End Optical Pyrometers Market worth $ 238.17 Million by 2020 4Health News:Suitor to receive GSA's 2014 Distinguished Career Contribution to Gerontology Award 2Health News:Harrington Meyer, Leist, Hessel, Avendano to receive GSA's 2014 Kalish awards 2Health News:No Exam Life Insurance - Coverage for Clients Who Have High Cholesterol 2
... ... educational stories, NEW YORK, May 12 ... Gamble Pharmaceuticals (P&G), has,selected seven winners for the Celebrating UC Success ... by ulcerative,colitis. Winners, stories reflect a wide variety of experiences with,ulcerative ...
... 12 FutureScripts(R), the premier,pharmacy benefit manager in ... . The website is a valuable tool for ... find key,information about the drugs on FutureScripts, formulary, ... "The new website allows our customers to find ...
... in French . , Montreal, May 12, 2008 ... in some cases, emotional and physical pain can linger for ... Universit de Montral graduate student Emma Duerden is inviting amputees ... study. , Our main goal is to better understand why ...
... homeless youth suggests that treating substance abuse and mental health ... the streets. , Instead, researchers found that creating more opportunities ... factors in reducing homelessness. , A study of 180 ... most social stability, such as those who attended school more ...
... is Disability Insurance Awareness Month; LIFE Foundation Reviews Common, Misconceptions to Encourage ... ... Needs, ARLINGTON, Va., May 12 If you were ... yourself,financially? The results of a new survey released today by the nonprofit,LIFE ...
... uncover ... system abuse, HORSEHEADS, N.Y., May ... in 2007. With so many recipients and,providers involved, the New York State ... abuse., Over the last two years, Salient Corporation, provider of the ...
Cached Medicine News:Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 2Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 3Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 4Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 5Health News:UPDATE: Celebrating UC Success Announces Essay Contest Winners 6Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 2Health News:Pharmacy Benefit Manager FutureScripts(R) Launches New Website 3Health News:Homeless youth need more than treatment for substance abuse, study says 2Health News:Homeless youth need more than treatment for substance abuse, study says 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 2Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 3Health News:New Survey Finds Overwhelming Majority of Working Americans Not Financially Prepared for Disability, Would Rely on Sources Other than Themselves for Support 4Health News:Salient Corporation's Performance Management Solution Helps NY State Counties Identify Medicaid Fraud, Waste, and Abuse 2
(Date:7/31/2014)... , July 31, 2014 Lazarus Effect, ... novel interventional devices to facilitate removal of blood clots, ... from the financing will support EU commercialization of several ... for the Lazarus ReCover™ and Lazarus Cover™ in ... financing reflects investor confidence in the value of our ...
(Date:7/31/2014)... Catylix, Inc. ( Burbank, California ... California ) announced today the formation of ... fluorination products and related chemistry. Developing ... use of substituents that are chemically stable, resistant ... improve binding and bioavailability. Fluorinated functional groups are ...
(Date:7/31/2014)... -- Zacks.com announces the list of stocks featured in the Analyst ... latest news and events impacting stocks and the financial markets. ... BIIB - Free Report ), Gilead (Nasdaq: GILD - ... Report ), AbbVie (NYSE: ABBV - Free Report ) ... Today, Zacks is promoting its ,Buy, stock recommendations. ...
Breaking Medicine Technology:Lazarus Effect Closes $5 Million Financing 2Catylix, Inc. and Aspira Scientific Announce Joint Venture to Commercialize New Fluorination Technologies 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 2The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 3The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 4The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 5The Zacks Analyst Blog Highlights: Biogen, Gilead, Puma Biotechnology, AbbVie and Celgene 6
... Phase III,clinical trial evaluating the efficacy and safety ... of postmenopausal osteoporosis were,presented at the American Society ... In the non-inferiority study comparing risedronate 150,mg once ... sodium,tablets)] increases in bone mineral density (BMD) were ...
... Sept. 19 Rockwell Medical,Technologies, Inc. (Nasdaq: ... and,developer of concentrates and specialty pharmaceuticals focused ... that it has commenced,enrollment in its Phase ... a physiological iron-maintenance therapy drug. The ...
Cached Medicine Technology:New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 2New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 3New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 4New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 5New Phase III Data Presented for Once Monthly Dosing Regimen of Risedronate to Treat Postmenopausal Osteoporosis 6Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 2Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 3Rockwell Medical Technologies, Inc. Begins Patient Enrollment for its SFP Dose-Ranging Study 4
... designed to validate HDL cholesterol plus other ... This control is compatible with most major ... Synchron and Vitros. HDL values are given ... methods: Dextran Sulfate 50,000 MW. Apolipoprotein A-1 ...
... is intended as a means ... ethanol assay methods. This ready-to-use, ... clinically significant levels of ammonia ... provided for the following instruments: ...
... This unassayed control is intended ... manual and automated assay methods ... oxalate in human urine samples. ... requiring no reconstitution. This control ...
... Microbumin is a two-level control ... Clinitek Microalbumin Reagent Strips and Roche ... also suitable for turbidimetric immunoassays using ... and DCA 2000, Cobas, Diasorin SPQ ...
Medicine Products: